Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions

Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions   Key clinical takeaways:   MMR status should be tested in all patients at diagnosis and upon disease progression to guide personalised treatment decisions   ICI and ChT combination, including with maintenance olaparib, demonstrates benefits in patients with non-dMMR advanced/recurrent endometrial cancer, with greater efficacy observed in dMMR populations  Lenvatinib plus pembrolizumab is a viable option not only as 2nd line therapy but also as 1st line treatment for patients with non-dMMR advanced/recurrent endometrial cancer who have progressed after prior systemic therapy in any setting  Shared decision-making, supported by patient education, is essential for optimising treatment outcomes   The treatment landscape for advanced and recurrent endometrial cancer (EC) is evolving, with molecular classification playing a key role in guiding decisions. In this podcast, Prof. Xavier Matias-Guiu (Pathologist) and Dr Jurjees Hasan (Medical Oncologist) discuss the latest advancements in personalised treatment approaches for EC.  Key topics include:  The role of molecular classification in guiding treatment selection and testing strategies  Treatment options for patients with pMMR status  Effective patient communication for shared decision-making  Tune in for expert insights and practical guidance to optimise treatment strategies in advanced and recurrent EC  You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/obstetrics-gynecology-connect/programmes/endometrial-cancer-molecular-classification-treatment-decisions/  Or watch on YouTube: https://youtu.be/KvYIB7PBpyQ    Follow us on social media:  LinkedIn: https://www.linkedin.com/company/ob-gyn-connect/?viewAsMember=true   X: https://x.com/OBGynConnect     This content is intended for healthcare professionals only.  The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this podcast.    This podcast is developed by cor2ed.com  Published February 2025    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

There are no comments yet.

Please log in to write the first comment.